# Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058)

> **NCT02203149** · PHASE2,PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 399 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Grazoprevir
- **DRUG:** Elbasvir
- **DRUG:** Placebo to Grazoprevir
- **DRUG:** Placebo to Elbasvir

## Key facts

- **NCT ID:** NCT02203149
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-01
- **Primary completion:** 2015-10-02
- **Final completion:** 2016-05-16
- **Target enrollment:** 399 (ACTUAL)
- **Last updated:** 2018-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02203149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02203149, "Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02203149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*